GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength

GE HealthCare Technologies

29/07/2026 11:30

Overview
Medical technology firm's Q2 revenue rose 5.7%, slightly beating analyst expectations
Adjusted EPS for Q2 beat consensus, rising 6.6% year-over-year
Company repurchased $200 mln in shares during the quarter

Outlook
GE HealthCare reaffirms 2026 organic revenue growth guidance of 3.0% to 4.0%
Company expects 2026 adjusted EPS of $4.80 to $5.00
GE HealthCare anticipates 2026 free cash flow of about $1.6 bln

Result Drivers
SEGMENT PERFORMANCE - Revenue growth was driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions continued to face challenges
TARIFF REFUNDS - Net income and EPS benefited from International Emergency Economic Powers Act tariff refunds recognized in the quarter
INFLATION PRESSURE - Margins were negatively impacted by inflation related to memory chips, oil and freight costs

Company press release: ID:nBw6x8bkJa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$5.30 bln
$5.26 bln (15 Analysts)
Q2 Adjusted EPS
Beat
$1.13
$1.04 (15 Analysts)
Q2 EPS
 
$1.24
 
Q2 Net Income
 
$561 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for GE Healthcare Technologies Inc is $80.00, about 24.8% above its July 28 closing price of $64.11
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
July 28 - Philips falls 9% as weak orders, China concerns overshadow outlook hike
July 29 - Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates
July 28 - IQVIA raises annual profit forecast on clinical research demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)